Teduglutide
FDA-approved GLP-2 analog for SBS (Gattex).
What it's for
Teduglutide is a recombinant GLP-2 analog resistant to DPP-4 degradation. It treats short bowel syndrome in patients dependent on parenteral support, aiming to increase intestinal absorption and reduce PN needs.
What it does for the body
It treats short bowel syndrome in patients dependent on parenteral support, aiming to increase intestinal absorption and reduce PN needs. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
GLP-2 receptors (lock-and-key landing spots on cells) activation promotes lining of the gut growth and improves nutrient/fluid absorption in remaining intestine. Think of it like turning up a dimmer switch on the body's natural "I'm full / handle sugar after meals" signal.
Research context
Bottom line for readers: Teduglutide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Teduglutide — FDA.gov search
- ClinicalTrials.gov search: Teduglutide — U.S. clinical trials registry
- Drugs@FDA search: Teduglutide — FDA drug database (if approved)
- PubMed search: Teduglutide — NCBI PubMed
- PubMed Central search: Teduglutide — NCBI PMC